ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Organon & Co

Organon & Co (7XP)

11,60
-0,005
(-0,04%)
Geschlossen 11 Juni 10:00PM

Organon & Co (7XP) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
11,60
( -0,04% )
Gebot
11,53
Fragen
11,65
Volumen
6.534
11,525 Tagesbereich 11,59
4,973 52-Wochen-Bereich 11,645
Marktkapitalisierung
Handelsende
11,605
Handelsbeginn
11,525
Letzte Trade
2000
@
11.575
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
8.679.439 €
Ausgegebene Aktien
262.600.862
Dividendenrendite (LTM)
0,08 (0,60%)
Kurs-Gewinn-Verhältnis
14,18
Gewinn pro Aktie (EPS)
0,94
Erlöse (LTM)
6,16B
Nettogewinn (LTM)
246M

Über Organon & Co

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comp... Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey. Mehr anzeigen

Sektor
Healthcare
Branche
Pharmaceuticals
Website
Hauptsitz
Jersey City, United States
Gegründet
2026
Organon & Co is listed in the Healthcare sector of the Tradegate (DE) with ticker 7XP. The last closing price for Organon & was 11,61 €. Over the last year, Organon & shares have traded in a share price range of 4,973 € to 11,645 €.

Organon & currently has 262.600.862 shares in issue. The market capitalisation of Organon & is 3,05 € billion. Organon & has a price to earnings ratio (PE ratio) of 14.18.

7XP Neueste Nachrichten

Keine Nachrichten vorhanden.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.1951.7097764138511.40511.64511.405157111.57786187DE
40.373.2947462154911.2311.64511.23312211.49313818DE
126.114111.4473204525.48611.6454.97369649.65182796DE
265.67895.87977034795.92211.6454.97355618.28453139DE
523.054000135.73601843838.545999911.6454.97350857.67918237DE
156-6.75-36.784741144418.3521.564.973316510.33363619DE
260-17.34-59.917069799628.9436.7354.973211810.92730098DE

7XP - Frequently Asked Questions (FAQ)

What is the current Organon & Co share price?
The current share price of Organon & Co is 11,60 €
How many Organon & Co shares are in issue?
Organon & Co has 262.600.862 shares in issue
What is the market cap of Organon & Co?
The market capitalisation of Organon & Co is EUR 3,05B
What is the 1 year trading range for Organon & Co share price?
Organon & Co has traded in the range of 4,973 € to 11,645 € during the past year
What is the PE ratio of Organon & Co?
The price to earnings ratio of Organon & Co is 14,18
What is the cash to sales ratio of Organon & Co?
The cash to sales ratio of Organon & Co is 0,57
What is the registered address of Organon & Co?
The registered address for Organon & Co is 30 Hudson Street, Jersey City, New Jersey, 07302
What is the Organon & Co website address?
The website address for Organon & Co is www.organon.com
Which industry sector does Organon & Co operate in?
Organon & Co operates in the Pharmaceuticals sector

7XP Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen